Entelos Evaluates Potential Asthma Treatments For Bayer

Entelos, Inc. has announced the completion of a professional services engagement with Bayer AG, to evaluate an IL-4 receptor antagonist as a potential treatment for asthmatics. Entelos applied their predictive asthma PhysioLab technology to Bayer’s proprietary animal model data in order to assess the impact of treatment on a variety of patient types and to Read more about Entelos Evaluates Potential Asthma Treatments For Bayer[…]

Bayer Diagnostics To Acquire Visible Genetics

Bayer Corporation, Diagnostics Division and Visible Genetics Inc. (VGI) have signed a definitive agreement providing for Bayer Diagnostics to acquire VGI in a cash deal valued at $61.4 million, significantly expanding Bayer’s position in the growing Nucleic Acid Diagnostic (NAD) segment of the Professional Laboratory market. Bayer will purchase, for cash consideration, VGI’s outstanding common Read more about Bayer Diagnostics To Acquire Visible Genetics[…]